Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Matson Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Matson Inc trades at $201.49 (market cap $6.01B). The key difference: Matson Inc is the larger of the two by market cap, and Matson Inc pays a 0.77% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MATX | |
|---|---|---|
Market Cap | $4.49B | $6.01B |
Sector | Health | Technology |
52-Week High | $28.06 | $204.53 |
52-Week Low | $20.06 | $88.05 |
Enterprise Value | $3.69B | $6.61B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Matson (MATX) trades at $204.53, up 0.49% with strong technical momentum near resistance at $206. The stock shows robust fundamentals with consistent earnings beats, a 12.92% net margin, and shareholder-friendly actions including dividend increases and share buybacks. Recent news highlights the company's niche Pacific shipping advantages and operational efficiency gains.
Outlook remains positive given analyst consensus (64% buy ratings) and strong profitability metrics, though risks include shipping rate volatility and macroeconomic sensitivity. The current valuation at 15.17x P/E appears reasonable for a company with double-digit ROE and dividend growth, positioning MATX as a quality mid-cap transportation play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
